DOCSLIB.ORG

The Luminal Progenitor Compartment of the Normal Human Mammary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Luminal Progenitor Compartment of the Normal Human Mammary University of Groningen The Luminal Progenitor Compartment of the Normal Human Mammary Gland Constitutes a Unique Site of Telomere Dysfunction Kannan, Nagarajan; Huda, Nazmul; Tu, LiRen; Droumeva, Radina; Aubert, Geraldine; Chavez, Elizabeth; Brinkman, Ryan R.; Lansdorp, Peter; Emerman, Joanne; Abe, Satoshi Published in: Stem Cell Reports DOI: 10.1016/j.stemcr.2013.04.003 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2013 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Kannan, N., Huda, N., Tu, L., Droumeva, R., Aubert, G., Chavez, E., Brinkman, R. R., Lansdorp, P., Emerman, J., Abe, S., Eaves, C., & Gilley, D. (2013). The Luminal Progenitor Compartment of the Normal Human Mammary Gland Constitutes a Unique Site of Telomere Dysfunction. Stem Cell Reports, 1(1), 28- 37. https://doi.org/10.1016/j.stemcr.2013.04.003 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Stem Cell Reports Report The Luminal Progenitor Compartment of the Normal Human Mammary Gland Constitutes a Unique Site of Telomere Dysfunction Nagarajan Kannan,1,5 Nazmul Huda,2,5 LiRen Tu,2 Radina Droumeva,1 Geraldine Aubert,1 Elizabeth Chavez,1 Ryan R. Brinkman,1 Peter Lansdorp,1,3 Joanne Emerman,4 Satoshi Abe,2 Connie Eaves,1,5,* and David Gilley2,5,* 1Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada 2Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202-5251, USA 3European Research Institute for the Biology of Ageing, University Medical Center Groningen, and University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands 4Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada 5These authors contributed equally to this work. *Correspondence: [email protected] (C.E.), [email protected] (D.G.) http://dx.doi.org/10.1016/j.stemcr.2013.04.003 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Telomeres are essential for genomic integrity, but little is known about their regulation in the normal human mammary gland. We now demonstrate that a phenotypically defined cell population enriched in luminal progenitors (LPs) is characterized by unusually short telomeres independently of donor age. Furthermore, we find that multiple DNA damage response proteins colocalize with telomeres in >95% of LPs but in <5% of basal cells. Paradoxically, 25% of LPs are still capable of exhibiting robust clonogenic activity in vitro. This may be partially explained by the elevated telomerase activity that was also seen only in LPs. Interestingly, this potential telomere salvage mechanism declines with age. Our findings thus reveal marked differences in the telomere biology of different subsets of primitive normal human mammary cells. The chronically dysfunctional telomeres unique to LPs have potentially important implications for normal mammary tissue homeostasis as well as the development of certain breast cancers. INTRODUCTION normal human mammary epithelial cells with distinct bio- logical properties have markedly different telomere lengths Chromosome ends, referred to as telomeres, contain repeat and telomerase activities. Interestingly, a phenotype that sequences (TTAGGG)n and associated proteins that protect is highly enriched in luminal progenitors (LPs) is uniquely cells from the formation of chromosome end-to-end characterized by critically short telomeres, frequent evi- fusions (Artandi and DePinho, 2010). In normal tissues, dence of a telomere-specific DNA damage response (DDR), such as in the hematopoietic system, where cell turnover and an age-related decrease in telomerase activity. is high and continuous throughout life, telomeres are main- tained in the most primitive cells at relatively long lengths and then become progressively shorter as the cells differen- RESULTS AND DISCUSSION tiate through multiple amplifying divisions and with age (Aubert and Lansdorp, 2008). Epithelial tissues, including Normal Human Mammary LPs Possess Short the mammary gland in both humans and mice, also un- Telomeres dergo extensive turnover, and recent studies indicated To examine telomere length in different compartments of that this may involve a similarly organized hierarchical normal human breast tissue and possible age-related differentiation process (Eirew et al., 2008; Visvader, 2009). changes, we isolated four phenotypically distinct subsets To date, analysis of telomere length regulation in normal of cells at high purities (>95%) from different normal reduc- mammary epithelial cells has been limited to reports of tion mammoplasty tissue samples obtained from donors of shorter telomeres in luminal cells (Kurabayashi et al., different ages and analyzed them directly, without culture 2008; Meeker et al., 2004), and human telomerase reverse (Figure 1A; Table S1 available online). We examined transcriptase (hTERT) messenger RNA (mRNA; Kolquist four subsets of cells: (1) a basal epithelial cell (BC) subset et al., 1998) in histological sections. However, the presence that is highly enriched in cells with bipotent as well as of telomere fusions was noted in primary mammary epithe- myoepithelial clonogenic activity in vitro (Figure 1B), (2) lial cells after their extensive passage in vitro (Romanov an LP subset that is similarly enriched in cells with luminal et al., 2001), and we recently reported that telomere- clonogenic activity in vitro (Figure 1B), (3) a third mam- dysfunction-specific chromosomal fusions are common mary epithelial cell subset that contains exclusively mature in early-stage breast cancers (Tanaka et al., 2012). Here luminal cells (LCs) with no clonogenic activity (Figure 1B), we show that phenotypically separable compartments of and (4) a population consisting of nonepithelial stromal 28 Stem Cell Reports j Vol. 1 j 28–37 j June 4, 2013 j ª2013 The Authors Stem Cell Reports Telomere Dysfunction in Breast Luminal Progenitors A Depletion of dead/blood/ endothelial cells CFC assay Fix, stain & score ~10 days Single cell Staining Isolation LC LP Luminal colony dissociation of subsets Normal mammary SC EpCAM BC tissue /CD31/CD45 Snap freeze Basal colony DAPI for telomere analysis SSC CD49f B C D 12 BC 12 LP 12 LC 12 SC 100 12 10 10 R² = 0.002 10 R² = 0.5 10 P = 0.9 P < 0.01 (kb) RF (kb) R R C C 10 10 8 8 8 8 1 8 6 6 6 6 0.1 R² = 0.05 R² = 0.08 6 Percentage of Percentage CF Telomere length - length Telomere T P = 0.5 P = 0.3 R² = 0.75 P < 0.0001 Telomere length - length Telomere qPC 0.01 4 4 4 4 4 BC LP LC 0 255075 0 255075 0 255075 0255075 4681012 Telomere length - TRF (kb) Age (years) Age 463146 20 26 E H Unstained BC Unstained LP Stained BC Stained LP Thymocytes Thymocytes HT1080 ladder EEC EEC TC TC SC SC SC BC LP LC BC LP LC BC LP LC 100 BC LP LC 80 Age 46 20 26 60 e (kb) maximum e of 40 23.1 20 Percentag 12.0 0 10.0 0 200 400 600 800 1000 0 200 400 600 800 1000 9.0 8.0 Telomere-PNA-FITC probe 7.0 6.0 I 5.0 4.3 4.0 3.0 2.4 2.0 0 100 0100100 0 % Maximum 1.5 BC LP 1.0 J 200 BC mean 6.3 kb FGFRT RCPq LP mean 3.4 kb P = 0.004 150 12 P < 0.001 12 11 11 P = 0.004 P < 0.001 (kb) (kb) 10 10 h h h 100 9 9 8 8 Frequency 7 7 50 6 6 5 5 Telomere lengt Telomere lengt 4 4 0 BC LP LC SC BC LP LC SC 0 3 6 9 12 15 18 21 24 27 30 Telomere fluourescene units (x1000) Figure 1. Telomere Length Alterations in Different Subsets of Cells Present in Normal Human Breast Tissue (A) Process for isolating and characterizing the four subsets of cells studied (after removal of CD45+ hematopoietic and CD31+ endothelial cells), showing examples of colonies obtained from cells in the LP (above) and BC (below) fractions. BCs are defined by their CD49fhiEpCAMneg/low phenotype and contain bipotent and self-renewing mammary stem cells identified by in vivo transplantation assays (legend continued on next page) Stem Cell Reports j Vol. 1 j 28–37 j June 4, 2013 j ª2013 The Authors 29 Stem Cell Reports Telomere Dysfunction in Breast Luminal Progenitors cells (SCs) that are still prominent after the hematopoietic mammary epithelial cells (on average 9 kb by southern and endothelial cells are removed (Figure 1A). Extracts of blot analysis), and also do not show significant changes in each of these four highly purified cell populations were telomere length with age (Figures 1C and 1E–1G).
Load more

Recommended publications
  • Amplification of Chromosome 8 Genes in Lung Cancer Onur Baykara1, Burak Bakir1, Nur Buyru1, Kamil Kaynak2, Nejat Dalay3
    Journal of Cancer 2015, Vol. 6 270 Ivyspring International Publisher Journal of Cancer 2015; 6(3): 270-275. doi: 10.7150/jca.10638 Research Paper Amplification of Chromosome 8 Genes in Lung Cancer Onur Baykara1, Burak Bakir1, Nur Buyru1, Kamil Kaynak2, Nejat Dalay3 1. Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University, Turkey 2. Department of Chest Surgery, Cerrahpasa Medical Faculty, Istanbul University, Turkey 3. Department of Basic Oncology, I.U. Oncology Institute, Istanbul University, Turkey Corresponding author: Prof. Dr. Nejat Dalay, I.U.Oncology Institute, 34093 Capa, Istanbul, Turkey. e-mail : [email protected]; Phone : 90 542 2168861; Fax : 90 212 5348078 © 2015 Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. Received: 2014.09.25; Accepted: 2014.12.18; Published: 2015.01.20 Abstract Chromosomal alterations are frequent events in lung carcinogenesis and usually display regions of focal amplification containing several overexpressed oncogenes. Although gains and losses of chromosomal loci have been reported copy number changes of the individual genes have not been analyzed in lung cancer. In this study 22 genes were analyzed by MLPA in tumors and matched normal tissue samples from 82 patients with non-small cell lung cancer. Gene amplifications were observed in 84% of the samples. Chromosome 8 was found to harbor the most frequent copy number alterations. The most frequently amplified genes were ZNF703, PRDM14 and MYC on chromosome 8 and the BIRC5 gene on chromosome 17. The frequency of deletions were much lower and the most frequently deleted gene was ADAM9.
    [Show full text]
  • Amplicons in Breast Cancers Analyzed by Multiplex Ligation-Dependent
    Human Pathology (2019) 85,33–43 www.elsevier.com/locate/humpath Original contribution Amplicons in breast cancers analyzed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization☆,☆☆ Akishi Ooi MD, PhD a,b,⁎, Masafumi Inokuchi MD, PhD c, Shin-ichi Horike PhD d, Hiroko Kawashima MD, PhD e, Satoko Ishikawa MD, PhD c, Hiroko Ikeda MD, PhD b, Ritsuko Nakamura MD, PhD a, Takeru Oyama MD, PhD a, Yoh Dobashi MD, PhD f aDepartment of Molecular and Cellular Pathology, Kanazawa University, Ishikawa 920-8641, Japan bPathology Section, University Hospital, Kanazawa University, Ishikawa 920-8641, Japan cDepartment of Breast Oncology, Graduate School of Medical Science, Kanazawa University, Ishikawa 920-8641, Japan dAdvanced Science Research Center, Institute for Gene Research, Kanazawa University, Ishikawa 920-8641, Japan eSection of Breast Oncology, University Hospital, Kanazawa University, Ishikawa 920-8641, Japan fDepartment of Pathology, Saitama Medical Center, Jichi Medical University, Saitama, 330-8503, Japan Received 16 August 2018; revised 12 October 2018; accepted 18 October 2018 Keywords: Summary Gene amplification is a common event in breast cancer, and identifies actual and potential targets of Breast cancer; molecular therapy. The aim of the present study was to determine the amplification status of 22 genes that are Gene amplification; reportedly frequently amplified in breast cancers. An archive of 322 formalin-fixed and paraffin-embedded in- FISH; vasive breast cancer tissues were screened by multiple ligation-dependent probe amplification (MLPA) and a MLPA; total of 906 gene loci judged as ‘gain’ or ‘amplified’ was further confirmed to have been amplified based on Co-amplication fluorescence in situ hybridization (FISH).
    [Show full text]
  • ZNF703 Overexpression May Act As an Oncogene In
    Cancer Medicine Open Access ORIGINAL RESEARCH ZNF703 Overexpression may act as an oncogene in non-small cell lung cancer Onur Baykara1, Nejat Dalay2, Kamil Kaynak3 & Nur Buyru1 1Department of Medical Biology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey 2Istanbul University Oncology Institute, Istanbul, Turkey 3Department of Chest Surgery, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey Keywords Abstract Akt/mTOR pathway, expression, NSCLC, ZNF703 Despite therapeutic advances, lung cancer remains one of the most common causes of cancer-­related deaths worldwide. The ZNF703 gene has been identified Correspondence as the driver of the 8p11-12­ region and its amplification or overexpression has Nur Buyru, Department of Medical Biology, been associated with several types of cancers. It has also been shown that ZNF703 Istanbul University Cerrahpasa Medical overexpression can activate the Akt/mTOR signaling pathway. The aim of our Faculty, Kat:6 Kocamustafapasa 34098, study was to investigate the role of the ZNF703 gene in association with Akt/mTOR Istanbul, Turkey. Tel: 90 505 5249471; Fax: 90 212 4143502; activation in non-small cell lung cancer (NSCLC). Expression levels in tumors E-mail: [email protected] and matched noncancerous tissue samples from 47 patients were analyzed by qRT-­PCR and the Akt phosphorylation levels were investigated by Western Funding Information blotting. Our results show that ZNF703 is up-regulated­ in 63.4% of NSCLC This project has been supported by the tumor samples. Althogh the correlation did not reach a statistically significant Scientific and Technological Research Council level Akt phosphorylation was increased in tumor tissues expressing high levels of Turkey (TUBITAK) by project number of ZNF703.
    [Show full text]
  • Levisticum Officinale Extract Triggers Apoptosis and Down-Regulates ZNF703 Gene Expression in Breast Cancer Cell Lines
    Reports of Biochemistry & Molecular Biology Vol.8, No.2, July 2019 Original article www.RBMB.net Levisticum Officinale Extract Triggers Apoptosis and Down-Regulates ZNF703 Gene Expression in Breast Cancer Cell Lines Fatemeh Mollashahee-Kohkan1, 2, Ramin Saravani*1, 2, Tahereh Khalili2, Hamidreza Galavi1, 2, Saman Sargazi1 Abstract Background: Studies have shown that zinc finger protein 703 (ZNF703) is overexpressed in breast cancer. Levisticum (L.) officinale is a herbal plant with proven medical characteristics in traditional medicine. The purpose of the present study was to evaluate the effect of hydroalcoholic extract of L. officinale (HELO) on both estrogen receptor-positive (ER+) and -negative (ER-) cell lines (MCF-7 and MDA-MB-468, respectively). Methods: The anti-proliferative and apoptotic activities of HELO were investigated on both cell lines using MTT and flow-cytometry methods. Real-time PCR was employed to determinate the changes in mRNA expression of the ZNF703 gene. + - Results: The 50% maximal inhibitory concentrations (IC50s) of HELO on ER and ER cells were 200 and 150 µg/mL after 48 h-treatment. Statistically significant increases in both early and late apoptosis rates were seen in exposed cell lines. ZNF703 expression was less from 4 to 24 h HELO treatment than in untreated cells, and ZNF703 expression was higher in the more invasive MDA-MB-468 cells than in the less invasive MCF-7 cells. Our results demonstrated that HELO induces apoptosis and decreases cell growth in both cell lines. Conclusions: Our data suggest that HELO alters the mRNA levels of ZNF703 gene while inducing apoptotic cell death in breast cancer-derived cell lines.
    [Show full text]
  • Landscape of Somatic Mutations in 560 Breast Cancer Whole-Genome
    ARTICLE doi:10.1038/nature17676 Landscape of somatic mutations in 560 breast cancer whole-genome sequences Serena Nik-Zainal1,2, Helen Davies1, Johan Staaf3, Manasa Ramakrishna1, Dominik Glodzik1, Xueqing Zou1, Inigo Martincorena1, Ludmil B. Alexandrov1,4,5, Sancha Martin1, David C. Wedge1, Peter Van Loo1,6, Young Seok Ju1, Marcel Smid7, Arie B. Brinkman8, Sandro Morganella9, Miriam R. Aure10,11, Ole Christian Lingjærde11,12, Anita Langerød10,11, Markus Ringnér3, Sung-Min Ahn13, Sandrine Boyault14, Jane E. Brock15, Annegien Broeks16, Adam Butler1, Christine Desmedt17, Luc Dirix18, Serge Dronov1, Aquila Fatima19, John A. Foekens7, Moritz Gerstung1, Gerrit K. J. Hooijer20, Se Jin Jang21, David R. Jones1, Hyung-Yong Kim22, Tari A. King23, Savitri Krishnamurthy24, Hee Jin Lee21, Jeong-Yeon Lee25, Yilong Li1, Stuart McLaren1, Andrew Menzies1, Ville Mustonen1, Sarah O’Meara1, Iris Pauporté26, Xavier Pivot27, Colin A. Purdie28, Keiran Raine1, Kamna Ramakrishnan1, F. Germán Rodríguez-González7, Gilles Romieu29, Anieta M. Sieuwerts7, Peter T. Simpson30, Rebecca Shepherd1, Lucy Stebbings1, Olafur A. Stefansson31, Jon Teague1, Stefania Tommasi32, Isabelle Treilleux33, Gert G. Van den Eynden18,34, Peter Vermeulen18,34, Anne Vincent-Salomon35, Lucy Yates1, Carlos Caldas36, Laura van’t Veer16, Andrew Tutt37,38, Stian Knappskog39,40, Benita Kiat Tee Tan41,42, Jos Jonkers16, Åke Borg3, Naoto T. Ueno24, Christos Sotiriou17, Alain Viari43,44, P. Andrew Futreal1,45, Peter J. Campbell1, Paul N. Span46, Steven Van Laere18, Sunil R. Lakhani30,47, Jorunn E. Eyfjord31, Alastair M. Thompson28,48, Ewan Birney9, Hendrik G. Stunnenberg8, Marc J. van de Vijver20, John W. M. Martens7, Anne-Lise Børresen-Dale10,11, Andrea L. Richardson15,19, Gu Kong22, Gilles Thomas44 & Michael R.
    [Show full text]
  • The Kinesin Spindle Protein Inhibitor Filanesib Enhances the Activity of Pomalidomide and Dexamethasone in Multiple Myeloma
    Plasma Cell Disorders SUPPLEMENTARY APPENDIX The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma Susana Hernández-García, 1 Laura San-Segundo, 1 Lorena González-Méndez, 1 Luis A. Corchete, 1 Irena Misiewicz- Krzeminska, 1,2 Montserrat Martín-Sánchez, 1 Ana-Alicia López-Iglesias, 1 Esperanza Macarena Algarín, 1 Pedro Mogollón, 1 Andrea Díaz-Tejedor, 1 Teresa Paíno, 1 Brian Tunquist, 3 María-Victoria Mateos, 1 Norma C Gutiérrez, 1 Elena Díaz- Rodriguez, 1 Mercedes Garayoa 1* and Enrique M Ocio 1* 1Centro Investigación del Cáncer-IBMCC (CSIC-USAL) and Hospital Universitario-IBSAL, Salamanca, Spain; 2National Medicines Insti - tute, Warsaw, Poland and 3Array BioPharma, Boulder, Colorado, USA *MG and EMO contributed equally to this work ©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2017.168666 Received: March 13, 2017. Accepted: August 29, 2017. Pre-published: August 31, 2017. Correspondence: [email protected] MATERIAL AND METHODS Reagents and drugs. Filanesib (F) was provided by Array BioPharma Inc. (Boulder, CO, USA). Thalidomide (T), lenalidomide (L) and pomalidomide (P) were purchased from Selleckchem (Houston, TX, USA), dexamethasone (D) from Sigma-Aldrich (St Louis, MO, USA) and bortezomib from LC Laboratories (Woburn, MA, USA). Generic chemicals were acquired from Sigma Chemical Co., Roche Biochemicals (Mannheim, Germany), Merck & Co., Inc. (Darmstadt, Germany). MM cell lines, patient samples and cultures. Origin, authentication and in vitro growth conditions of human MM cell lines have already been characterized (17, 18). The study of drug activity in the presence of IL-6, IGF-1 or in co-culture with primary bone marrow mesenchymal stromal cells (BMSCs) or the human mesenchymal stromal cell line (hMSC–TERT) was performed as described previously (19, 20).
    [Show full text]
  • The Long Noncoding RNA SPRY4-IT1 Increases the Proliferation of Human Breast Cancer Cells by Upregulating ZNF703 Expression
    Shi et al. Molecular Cancer (2015) 14:51 DOI 10.1186/s12943-015-0318-0 RESEARCH Open Access The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression Yongguo Shi1,2, Juan Li1, Yangchen Liu2, Jie Ding1, Yingrui Fan1, Yun Tian1, Li Wang1, Yifan Lian1, Keming Wang1* and Yongqian Shu3* Abstract Background: Long noncoding RNAs (lncRNAs) have emerged recently as a new class of genes that regulate cellular processes, such as cell growth and apoptosis. The SPRY4 intronic transcript 1 (SPRY4-IT1) is a 708-bp lncRNA on chromosome 5 with a potential functional role in tumorigenesis. The clinical significance of SPRY4-IT1 and the effect of SPRY4-IT1 on cancer progression are unclear. Methods: Quantitative reverse transcriptase PCR (qRT-PCR) was performed to investigate the expression of SPRY4-IT1 in 48 breast cancer tissues and four breast cancer cell lines. Gain and loss of function approaches were used to investigate the biological role of SPRY4-IT1 in vitro. Microarray bioinformatics analysis was performed to identify the putative targets of SPRY4-IT1, which were further verified by rescue experiments, and by western blotting and qRT-PCR. Results: SPRY4-IT1 expression was significantly upregulated in 48 breast cancer tumor tissues comparedwith normal tissues. Additionally, increased SPRY4-IT1 expression was found to be associated with a larger tumor size and an advanced pathological stage in breast cancer patients. The knockdown of SPRY4-IT1 significantly suppressed proliferation and caused apoptosis of breast cancer cells in vitro. Furthermore, we discovered that ZNF703 was a target of SPRY4-IT1 and was downregulated by SPRY4-IT1 knockdown.
    [Show full text]
  • The Development of a Dual-Tag Affinity Purification System and Its
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 12-2008 The Development of a Dual-Tag Affinity Purification System and its Application to Elucidate the Interacting Protein Network Surrounding the Human Telomere Binding Proteins TRF1, TRF2, and POT1 Richard John Giannone University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Giannone, Richard John, "The Development of a Dual-Tag Affinity Purification System and its Application to Elucidate the Interacting Protein Network Surrounding the Human Telomere Binding Proteins TRF1, TRF2, and POT1. " PhD diss., University of Tennessee, 2008. https://trace.tennessee.edu/utk_graddiss/523 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Richard John Giannone entitled "The Development of a Dual-Tag Affinity Purification System and its Applicationo t Elucidate the Interacting Protein Network Surrounding the Human Telomere Binding Proteins TRF1, TRF2, and POT1." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Life Sciences. Yisong Wang, Major Professor We have read this dissertation and recommend its acceptance: Yie Liu, W.
    [Show full text]
  • Dynamics of Breast Cancer Relapse Reveal Late Recurring 2 ER-Positive Genomic Subgroups 3 Oscar M
    1 Dynamics of breast cancer relapse reveal late recurring 2 ER-positive genomic subgroups 3 Oscar M. Rueda1,2, Stephen-John Sammut1,2+, Jose A Seoane3,4,5+, Suet-Feung 4 Chin1,2, Jennifer L Caswell-Jin3, , Maurizio Callari1,2, Rajbir Batra1,2, Bernard 5 Pereira1,2, Alejandra Bruna1,2, H Raza Ali1,2, Elena Provenzano6,7, Bin Liu2, Michelle 6 Parisien8, Cheryl Gillett9, Steven McKinney10, Andrew R. Green11, Leigh Murphy8, 7 Arnie Purushotham9, Ian O. Ellis11, Paul D. Pharoah 2, 6. 7, 12, Cristina Rueda13, 8 Samuel AJR Aparicio10, Carlos Caldas1,2,6,7*, Christina Curtis3,4,5*. 9 10 1 Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka 11 Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK 12 2 Cancer Research UK Cambridge Cancer Centre, Department of Oncology, Li Ka 13 Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK 14 3 Department of Medicine, Division of Oncology, Stanford University School of 15 Medicine, Stanford, California, USA 16 4 Department of Genetics, Stanford University School of Medicine, Stanford, 17 California, USA 18 5 Stanford Cancer Institute, Stanford University School of Medicine, Stanford, 19 California, USA 20 6 Cambridge Breast Unit, Addenbrooke’s Hospital, Cambridge University Hospital 21 NHS Foundation Trust. Cambridge CB2 2QQ, UK 22 7 NIHR Cambridge Biomedical Research Centre and Cambridge Experimental 23 Cancer Medicine Centre, Cambridge University Hospitals NHS, Hills Road, 24 Cambridge CB2 0QQ, UK 25 8 Research Institute in Oncology and Hematology,
    [Show full text]
  • And Radiotherapy Response in Breast Cancer
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 24), pp: 17078-17092 Research Paper Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer Cathy B. Moelans1, Caroline M. G. van Maldegem2, Elsken van der Wall3 and Paul J. van Diest1 1Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands 2Department of Gynaecology, Albert Schweitzer Hospital, Dordrecht, The Netherlands 3Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands Correspondence to: Cathy B. Moelans, email: [email protected] Keywords: breast cancer; loss; prognostic; predictive; 8p Received: November 30, 2017 Accepted: March 12, 2018 Published: March 30, 2018 Copyright: Moelans et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Purpose: The short arm of chromosome 8 (8p) is a frequent target of loss of heterozygosity (LOH) in cancer, and 8p LOH is commonly associated with a more aggressive tumor phenotype. The 8p11-12 region is a recurrent breakpoint area characterized by a sharp decrease in gains/amplifications and increase in allelic loss towards 8pter. However, the clustering of genomic aberrations in this region, even in the absence of proximal amplifications or distal LOH, suggests that the 8p11-12 region could play a pivotal role in oncogenesis. Results: Loss in the FGFR1 and ZNF703-containing 8p11 region was seen in 25% of patients, correlated with lower mRNA expression levels and independently predicted poor survival, particularly in systemic treatment-naïve patients and even without adjacent 8p12 loss.
    [Show full text]
  • High Expression of ZNF703 Independent of Amplification
    Cancer Medicine Open Access ORIGINAL RESEARCH High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer Inga Reynisdottir1, Adalgeir Arason1,2, Berglind O. Einarsdottir1, Haukur Gunnarsson1, Johan Staaf3,4, Johan Vallon-Christersson3,4, Goran Jonsson3,4, Markus Ringner 3,4, Bjarni A. Agnarsson1,2, Kristrun Olafsdottir1, Rainer Fagerholm6, Thorbjorg Einarsdottir1, Gudrun Johannesdottir1, Oskar Thor Johannsson5, Heli Nevanlinna6, Ake Borg3,4 & Rosa Bjork Barkardottir1,2 1Department of Pathology, Landspitali-University Hospital, 101, Reykjavik, Iceland 2BMC, Faculty of Medicine, University of Iceland, 101, Reykjavik, Iceland 3Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, SE 22185, Lund, Sweden 4CREATE Health Strategic Center for Translational Cancer Research, Lund University, BMC C13, SE 22184, Lund, Sweden 5Department of Oncology, Landspitali-University Hospital, 101, Reykjavik, Iceland 6Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland Keywords Abstract 8p12-p11 amplification, ER positive, luminal tumors, prognosis, tumor progression, Amplification of 8p12-p11 is relatively common in breast cancer and several ZNF703 genes within the region have been suggested to affect breast tumor progression. The aim of the study was to map the amplified 8p12-p11 region in a large set Correspondence of breast tumors in an effort to identify the genetic driver and to explore its Inga Reynisdottir, Department of Pathology, impact on tumor progression and prognosis. Copy number alterations (CNAs) Landspitali-University Hospital, 101 Reykjavik, were mapped in 359 tumors, and gene expression data from 577 tumors (359 Iceland. Tel: +354-543-8058; Fax +354-543- tumors included) were correlated with CNA, clinical–pathological factors, and 8349; E-mail: [email protected] protein expression (39 tumors).
    [Show full text]
  • Co-Amplified Genes at 8P12 and 11Q13 in Breast Tumors Cooperate
    Oncogene (2009) 28, 1892–1903 & 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00 www.nature.com/onc ORIGINAL ARTICLE Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis SS Kwek1,7, R Roy2, H Zhou1,8, J Climent1,3, JA Martinez-Climent4, J Fridlyand2,5,9 and DG Albertson1,2,6 1Cancer Research Institute, University of California San Francisco, San Francisco, CA, USA; 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; 3Department of Hematology and Medical Oncology, Hospital Clinico, Valencia, Spain; 4Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain; 5Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA and 6Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA Co-amplification at chromosomes 8p11–8p12 and 11q12– Introduction 11q14 occurs often in breast tumors, suggesting possible cooperation between genes in these regions in oncogenesis. Amplifications involving chromosomes 8p (RAB11- We used high-resolution array comparative genomic hybri- FIP1, FGFR1), 11q (CCND1) and 17q (ERBB2) are dization (array CGH) to map the minimal amplified regions. among the most common high-level copy number The 8p and 11q amplicons are complex and consist of at aberrations in breast tumors, occurring, for example, least four amplicon cores at each site. Candidate oncogenes in one study, in 22.8, 19.6 and 9.9% of tumors, mapping to these regions were identified by combining copy respectively (Letessier et al., 2006). Amplification of 8p number and RNA and protein expression analyses.
    [Show full text]